A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.

Tatsuya ToyamaAkiyo YoshimuraTakako HayashiNaomi KobayashiKanako SaitoMichiko TsuneizumiMasataka SawakiMasaya HattoriTakumi NakadaIsao YokotaHiroji Iwata

Published in: Breast cancer (Tokyo, Japan) (2018)

Prophylactic pyridoxine was not shown to have an effect on the onset of capecitabine-associated HFS in this study.

Keyphrases

phase ii study
metastatic breast cancer
locally advanced
open label
rectal cancer
placebo controlled
squamous cell carcinoma
clinical trial
case report
phase iii
metastatic colorectal cancer